ClinicalTrials.gg
CompletedNCT07743879Updated Aug 4, 2026

Comparative Efficacy of Therapeutic Ultrasound and Neurodynamic Techniques for Carpal Tunnel Syndrome

An interventional study of Neurodynamic Techniques in Carpal Tunnel Syndrome (CTS), sponsored by IBB University. Completed at 1 site in Yemen. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by IBB University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Feb 2025, registered Jul 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

This randomized controlled trial compares the efficacy of therapeutic ultrasound alone, neurodynamic techniques alone, and combined therapeutic ultrasound and neurodynamic techniques in patients with mild to moderate carpal tunnel syndrome.

Read the detailed description

This three-arm parallel-group randomized controlled trial evaluated the comparative efficacy of therapeutic ultrasound (US), neurodynamic techniques (ND), and combined US plus ND in 60 participants with mild to moderate carpal tunnel syndrome over a 6-week intervention period. The primary outcomes measured were pain intensity via visual analog scale (VAS) and symptom severity and functional status using the Boston Carpal Tunnel Questionnaire (BCTQ). Secondary outcomes evaluated nerve conduction parameters including distal motor latency (DML), sensory latency (SL), and sensory nerve action potential (SNAP) amplitude.

02

Conditions studied

  • Carpal Tunnel Syndrome (CTS)

Keywords

  • therapeutic ultrasound
  • neurodynamic techniques
  • nerve conduction study
  • conservative management
03

In context

Carpal Tunnel Syndrome

587 studies on the registry are indexed under Carpal Tunnel Syndrome; 134 are open to participants now.

This study's enrollment of 60 is close to the median of 60 across 443 interventional studies indexed under Carpal Tunnel Syndrome.

Browse Carpal Tunnel Syndrome studies →

Lead sponsor

IBB University is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of mild to moderate carpal tunnel syndrome confirmed by electrophysiological testing.
  • Age between 18 and 65 years.
  • Presence of symptoms (pain, numbness, tingling) for at least 3 months.

Exclusion criteria

Exclusion Criteria:

  • History of previous carpal tunnel release surgery or wrist trauma.
  • injection into the wrist within the past 3 months.
  • Cervical radiculopathy, polyneuropathy, or other upper extremity neurological disorders.
  • Pregnancy or lactation.
  • to therapeutic ultrasound (e.g., active infection, metallic implants in the treatment area, malignant tumors).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Therapeutic Ultrasound Group

    Continuous therapeutic ultrasound applied to the volar wrist at 1.5 W/cm² for 8 to 10 minutes per session, 3 times per week for 6 weeks.

    Other: Neurodynamic Techniques

  • Experimental
    Neurodynamic Techniques Group

    Median nerve neurodynamic mobilization (progressing from sliders to tensioners), 3 sets of 10 repetitions, 3 times per week for 6 weeks.

    Other: Neurodynamic Techniques

  • Experimental
    Combined Therapy Group

    Combined application of therapeutic ultrasound followed by neurodynamic techniques in the same session, 3 times per week for 6 weeks.

    Other: Neurodynamic Techniques

Interventions

  • OtherNeurodynamic Techniques

    Median nerve neurodynamic mobilization (progressing from sliders to tensioners), 3 sets of 10 repetitions.

06

What researchers measure

Primary outcomes

  1. Pain Intensity

    Measure Description: Measured using the unabbreviated Visual Analog Scale (VAS). This scale ranges from 0 to 10 cm, where 0 represents no pain and 10 represents the worst imaginable pain. Higher scores indicate a worse outcome (greater pain intensity).

    Time frame: Baseline and 6 weeks post-intervention

  2. Symptom Severity

    Measure Description: Assessed using the unabbreviated Boston Carpal Tunnel Questionnaire Symptom Severity Scale (BCTQ-SSS). The scale ranges from 1 to 5, with higher scores indicating a worse outcome (more severe symptoms).

    Time frame: Baseline and 6 weeks post-intervention

  3. Functional Status

    Measure Description: Assessed using Boston Carpal Tunnel Questionnaire Functional Status Scale (BCTQ-FSS). The scale ranges from 1 to 5, with higher scores indicating a worse outcome (greater functional disability/impairment).

    Time frame: Baseline and 6 weeks post-intervention

07

Study locations

1 site
  • Ibb University
    Ibb, nine, Yemen
08

References and documents

Individual participant data

Plan to share: No — Not applicable as there is no current plan to share individual participant data publicly.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07743879
Lead sponsor
IBB University
Collaborators
Al-Razi University
Responsible party
Faisal Ahmed (Assistant Professor and Head of the Department of Human Medicine, IBB University) — Principal investigator
First posted
Aug 4, 2026
Start date
Feb 25, 2025
Primary completion
Nov 1, 2025
Completion
Nov 26, 2025
Last update
Aug 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion